Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview

Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in palliative setting and last but not least, systemic treatment. The la...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Authors:	Diederick J. van Doorn, Robert Bart Takkenberg, Heinz-Josef Klümpen
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Subjects:	hepatocellular carcinoma (HCC), immunotherapy systemic therapy checkpoint inhibition outcome toxicity tolerability
Online Access:	https://www.mdpi.com/1424-8247/14/1/3

Similar Items

Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
by: Ran Qin, et al.
Published: (2023-12-01)

The role of the innate immune system in the development and treatment of hepatocellular carcinoma
by: Christoph Roderburg, et al.
Published: (2020-03-01)

Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature
by: Xiaoting Zhong, et al.
Published: (2025-08-01)

On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information
by: Tessa Hattenhauer, et al.
Published: (2025-10-01)

Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
by: Zeynep Akbulut, et al.
Published: (2024-04-01)

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
by: Muhammet Ozer, et al.
Published: (2021-12-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Vito Longo, et al.
Published: (2019-10-01)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
by: Jin Zhang, et al.
Published: (2023-03-01)

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
by: Shengwei Tao, et al.
Published: (2023-01-01)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
by: Mohamed A. Abd El Aziz, et al.
Published: (2020-10-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Samantha M. Ruff, et al.
Published: (2023-06-01)

Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy
by: Suoyi Dai, et al.
Published: (2025-09-01)

Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review
by: Chunhong Tian, et al.
Published: (2024-02-01)

Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)
by: F. van Bömmel, et al.
Published: (2023-10-01)

Research Progress on Immune Checkpoint Inhibitors in Treatment of Hepatocellular Carcinoma
by: CAO Jiali, et al.
Published: (2023-05-01)

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
by: Hsu HM, et al.
Published: (2023-10-01)

Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
by: Tong Liu, et al.
Published: (2024-08-01)

Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study
by: Li Pang, et al.
Published: (2025-09-01)

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
by: Hong-Fei Zhu, et al.
Published: (2023-06-01)

Editorial: Prognostic factors in hepatocellular carcinoma
by: Liliana Chemello, et al.
Published: (2023-11-01)

Bibliometric study of immunotherapy for hepatocellular carcinoma
by: Zhiyi Li, et al.
Published: (2023-08-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

A bibliometric and visual analysis based on immune checkpoint inhibitors for hepatocellular carcinoma: 2014 – 2024
by: Gao-Min Liu, et al.
Published: (2025-04-01)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
by: Jingyu Jiang, et al.
Published: (2023-02-01)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01)

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
by: Rujia Zhang, et al.
Published: (2023-12-01)

Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma
by: Fen Liu, et al.
Published: (2025-08-01)

The Immunology of Hepatocellular Carcinoma
by: Gbemisola Lawal, et al.
Published: (2021-10-01)

Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
by: Xiufeng Liu, et al.
Published: (2024-01-01)

Cellular senescence-related genes: predicting prognosis in hepatocellular carcinoma
by: Weiwei Yuan, et al.
Published: (2023-10-01)

NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma
by: Jiajia Du, et al.
Published: (2024-08-01)

Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma
by: Genhao Zhang, et al.
Published: (2022-08-01)

Bibliometric analysis of immune checkpoint inhibitors to treat hepatocellular carcinoma in patients with liver transplantation
by: Yanjiao Ou, et al.
Published: (2025-01-01)

Myasthenia Gravis-Like Symptoms Following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: A Case Report
by: Ha F, et al.
Published: (2025-08-01)

Cardiotoxicity of checkpoint inhibitors: focus on immune side effects
by: Yuri I. Buziashvili, et al.
Published: (2024-04-01)

Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice
by: Jun Gu, et al.
Published: (2024-12-01)

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
by: Yumeng Zhang, et al.
Published: (2022-08-01)

Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?
by: Elias Kouroumalis, et al.
Published: (2022-10-01)

Dynamics trajectory of patient-reported quality of life and its associated risk factors among hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a prospective cohort study
by: Xue-Mei You, et al.
Published: (2024-11-01)